BioXcel Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2025
Filed with the SEC on Aug 12, 2025 and accepted by EDGAR at Aug 12, 2025, 09:02 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-04-01 to 2025-06-30 | $120.0k | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2025-01-01 to 2025-06-30 | $288.0k | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2025-04-01 to 2025-06-30 | $107.0k | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2025-01-01 to 2025-06-30 | $121.0k | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months2025-04-01 to 2025-06-30 | $10.3m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2025-01-01 to 2025-06-30 | $14.8m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2025-04-01 to 2025-06-30 | $5.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2025-01-01 to 2025-06-30 | $11.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2025-04-01 to 2025-06-30 | −$15.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2025-01-01 to 2025-06-30 | −$26.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2025-04-01 to 2025-06-30 | $4.2m | us-gaap:InterestExpenseNonoperating |
| Interest expense | 6 months2025-01-01 to 2025-06-30 | $8.2m | us-gaap:InterestExpenseNonoperating |
| Net income | 3 months2025-04-01 to 2025-06-30 | −$19.2m | us-gaap:NetIncomeLoss |
| Net income | 6 months2025-01-01 to 2025-06-30 | −$26.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-04-01 to 2025-06-30 | −$2.45 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2025-01-01 to 2025-06-30 | −$4.17 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-04-01 to 2025-06-30 | −$2.45 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2025-01-01 to 2025-06-30 | −$4.17 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-04-01 to 2025-06-30 | 7,843,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2025-01-01 to 2025-06-30 | 6,347,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2025-01-01 to 2025-06-30 | −$24.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2025-01-01 to 2025-06-30 | $0 | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2025-06-30 | $17.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-06-30 | $25.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-06-30 | $25.8m | us-gaap:Assets |
| Current liabilities | At period end2025-06-30 | $33.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-06-30 | $133.5m | us-gaap:Liabilities |
| Long-term debt | At period end2025-06-30 | $97.5m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2025-06-30 | $11.2m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2025-06-30 | −$107.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-25-011158. Last ingested by Listed: Oct 30, 2026, 17:24 ET. Listed shows no prices and gives no investment advice.